RhumbLine Advisers
KZIA

RhumbLine Advisers’s Kazia Therapeutics KZIA Stock Holding History

RhumbLine Advisers’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2K Sell
1,296
-106
-8% -$1.29K ﹤0.01% 3827
2026
Q1 		$10.4K Sell
1,402
-163
-10% -$1.14K ﹤0.01% 3801
2025
Q4 		$10.8K Buy
1,565
+974
+165% +$8.3K ﹤0.01% 3845
2025
Q3 		$4.32K Hold
591
– – ﹤0.01% 3925
2025
Q2 		$3.66K Buy
591
+209
+55% +$976 ﹤0.01% 3945
2025
Q1 		$1.49K Sell
382
-174
-31% -$1.03K ﹤0.01% 4004
2024
Q4 		$4.91K Hold
556
– – ﹤0.01% 3960
2024
Q3 		$12K Buy
556
+204
+58% +$4.07K ﹤0.01% 3867
2024
Q2 		$4.01K Buy
352
+109
+45% +$1.62K ﹤0.01% 4116
2024
Q1 		$3.83K Buy
243
+49
+25% +$734 ﹤0.01% 4016
2023
Q4 		$4.36K Buy
194
+43
+28% +$1.26K ﹤0.01% 4006
2023
Q3 		$7.55K Hold
151
– – ﹤0.01% 3915
2023
Q2 		$8.61K Buy
+151
New +$9.52K ﹤0.01% 3983

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers's KZIA Position: Q2 2026 in Review

RhumbLine Advisers reduced its Kazia Therapeutics (KZIA) stake by 7.6% in Q2 2026, selling an estimated $1.29K and leaving 1,296 shares worth $18.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3827.

RhumbLine Advisers first reported a position in KZIA in Q2 2023 and has held it in 13 quarters since. 35 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • RhumbLine Advisers held 1,296 shares of Kazia Therapeutics worth $18.2K as of Q2 2026.
  • RhumbLine Advisers sold 106 Kazia Therapeutics shares in Q2 2026, an estimated $1.29K.
  • Kazia Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3827 holding.
  • RhumbLine Advisers first reported a position in Kazia Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 35 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.